As of November 10, 2026, Ocular Therapeutix, Inc. is a publicly traded company (Nasdaq: OCUL); its largest reported holder is Fidelity (FMR), with 15% on Schedule 13G/A of November 5, 2025, then Deep Track Capital (9.53%). The largest insider holding is Pravin Dugel, a director, with 3,270,332 shares (1.5% of shares outstanding), per Form 4 of August 26, 2026 (Schedule 13G/A, November 5, 2025).
Is this your company?
About to sign with, pay or invest in Ocular Therapeutix, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Ocular Therapeutix, Inc. a real, registered company?
- Ocular Therapeutix, Inc files with the SEC under CIK 1393434 (its SEC filings).
- Its shares are listed under the ticker OCUL on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Bedford, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under OCULAR THERAPEUTIX, INC in our court records and SEC 8-K records (as of 2026-11-10).
- Leadership changes: the latest reported is Riad Sherif, Director (Form 8-K filed 2026-11-09). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-07-29).
Who are Ocular Therapeutix, Inc.'s owners and officers?
Ocular Therapeutix, Inc.: incorporated in Delaware; business address in Bedford, Massachusetts; industry Pharmaceutical Preparations (Form D, 2026-11-09).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-07-29 | Blackrock, Inc. | 7% |
| Schedule 13G/A, 2026-05-15 | Deep Track Capital, LP | 9.53% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Venrock Healthcare Capital Partners Iii, L.P. | 3.2% |
| Schedule 13G/A, 2026-02-10 | Deep Track Capital, LP | 4.31% |
| Schedule 13G, 2026-02-10 | Deep Track Capital, LP | 5.13% |
| Schedule 13G, 2025-12-08 | Summer Road LLC | 5.7% |
| Schedule 13G/A, 2025-11-14 | Venrock Healthcare Capital Partners Iii, L.P. | 7.3% |
| Schedule 13G/A, 2025-11-14 | Deep Track Capital, LP | 6.18% |
| Schedule 13G/A, 2025-11-05 | Fmr LLC | 15% |
| Schedule 13G/A, 2025-10-17 | Blackrock, Inc. | 5.8% |
| Schedule 13G, 2025-07-08 | Fmr LLC | 12.3% |
Questions about who owns Ocular Therapeutix, Inc.
Who owns Ocular Therapeutix, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Ocular Therapeutix, Inc.: Fmr LLC (15%, Schedule 13G/A, filed 2025-11-05), Deep Track Capital, LP (9.53%, Schedule 13G/A, filed 2026-05-15), Blackrock, Inc. (7%, Schedule 13G/A, filed 2026-07-29) and Summer Road LLC (5.7%, Schedule 13G, filed 2025-12-08).
Who are the largest shareholders of Ocular Therapeutix, Inc.?
By the share each holder's latest filing reports, the largest holders of Ocular Therapeutix, Inc. on this page are Fmr LLC (15%), Deep Track Capital, LP (9.53%) and Blackrock, Inc. (7%).
When did Fmr LLC buy into Ocular Therapeutix, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2025-07-08, reporting 12.3%; its latest, Schedule 13G/A filed 2025-11-05, reports 15%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Ocular Therapeutix, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ocular Therapeutix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ocular Therapeutix, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-09 | Riad Sherif | Director | appointed | |
| Form 8-K, 2026-11-09 | Seung Suh Hong | departed | 2026-12-31 | |
| Form 8-K, 2026-06-12 | Jason Robins | Chief Financial Officer | appointed |
Which insiders own Ocular Therapeutix, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 3,270,332 shares (1.5% of shares outstanding), 2,525,429 held directly and 744,903 indirectly (Form 4, 2026-08-26).
- , the chief operating officer: 366,529 shares (0.17% of shares outstanding) (Form 4, 2026-09-02).
- , the chief strategy officer: 326,898 shares (0.15% of shares outstanding) (Form 4, 2026-08-26).
- , the chief scientific officer: 307,457 shares (0.14% of shares outstanding) (Form 4, 2026-10-06).
- , the chief medical officer: 300,079 shares (0.14% of shares outstanding) (Form 4, 2026-06-05).
Shares outstanding: 220,022,840 as of 2026-11-06, from the company's latest SEC cover page.
How much has Ocular Therapeutix, Inc. raised?
No fundraising or offering filing from Ocular Therapeutix, Inc. is on file with us.
Keep reading
More on Ocular Therapeutix, Inc. and the records around it.
Ocular Therapeutix, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Leadership changes Jun 2026
Companies that share a holder
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/ocular-therapeutix